Literature DB >> 16758472

A brief overview of mechanisms of mitochondrial toxicity from NRTIs.

James J Kohler1, William Lewis.   

Abstract

Nucleoside reverse transcriptase inhibitors (NRTIs) in combinations with other antiretrovirals (highly active antiretroviral therapy, HAART) are the cornerstones of AIDS therapy, turning HIV infection into a manageable clinical entity. Despite the initial positive impact of NRTIs, therapeutic experience revealed serious side effects that appeared to originate in the mitochondria and which ultimately manifested as dysfunction of that organelle. It may be reasonable to consider that as the AIDS epidemic continues and as survival with HIV infection is prolonged by treatment with HAART, long-term side effects of NRTIs may become increasingly common. This consideration may be underscored in children who are born to HIV-infected mothers who received NRTI therapy in utero during gestation. The long-term effect of that NRTI exposure in utero is not clear yet. This review examines some proposed mechanisms of NRTI mitochondrial toxicity, including genetic predisposition, defects in mitochondria DNA replication, the encompassing "DNA pol-gamma hypothesis," the relationship between mitochondrial nucleotide and NRTI pools, mitochondrial DNA mutation and dysfunction, and oxidative stresses related to HIV infection and NRTIs. Mechanisms of mitochondrial toxicity are reviewed with respect to key cell biological, pathological, and pharmacological events. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16758472     DOI: 10.1002/em.20223

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  64 in total

1.  Lower brain glutamate is associated with cognitive deficits in HIV patients: a new mechanism for HIV-associated neurocognitive disorder.

Authors:  Thomas Ernst; Caroline S Jiang; Helenna Nakama; Steven Buchthal; Linda Chang
Journal:  J Magn Reson Imaging       Date:  2010-11       Impact factor: 4.813

2.  Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection.

Authors:  Andrew C Young; Constantin T Yiannoutsos; Manu Hegde; Evelyn Lee; Julia Peterson; Rudy Walter; Richard W Price; Dieter J Meyerhoff; Serena Spudich
Journal:  Neurology       Date:  2014-09-26       Impact factor: 9.910

Review 3.  Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals.

Authors:  Vitaly A Kushnir; William Lewis
Journal:  Fertil Steril       Date:  2011-06-30       Impact factor: 7.329

Review 4.  Inherited mitochondrial genomic instability and chemical exposures.

Authors:  Sherine S L Chan
Journal:  Toxicology       Date:  2017-07-26       Impact factor: 4.221

Review 5.  Structure and function of Zika virus NS5 protein: perspectives for drug design.

Authors:  Boxiao Wang; Stephanie Thurmond; Rong Hai; Jikui Song
Journal:  Cell Mol Life Sci       Date:  2018-02-08       Impact factor: 9.261

Review 6.  HIV-exposed uninfected children: a growing population with a vulnerable immune system?

Authors:  L Afran; M Garcia Knight; E Nduati; B C Urban; R S Heyderman; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

7.  Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.

Authors:  Kaleb C Lund; LaRae L Peterson; Kendall B Wallace
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

8.  Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study.

Authors:  Phumla Z Sinxadi; Joel A Dave; David C Samuels; Jeannine M Heckmann; Gary Maartens; Naomi S Levitt; C William Wester; David W Haas; Todd Hulgan
Journal:  AIDS Res Hum Retroviruses       Date:  2013-03-15       Impact factor: 2.205

9.  Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations.

Authors:  Young-Sam Lee; W Dexter Kennedy; Y Whitney Yin
Journal:  Cell       Date:  2009-10-16       Impact factor: 41.582

10.  Tenofovir-associated bone density loss.

Authors:  Iwen F Grigsby; Lan Pham; Louis M Mansky; Raj Gopalakrishnan; Kim C Mansky
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.